Considering autotaxin inhibitors in terms of 2D-QSAR and 3D-mapping-review and evaluation

Current Medicinal Chemistry

Volumn 22, Issue 12, 2015, Pages 1428-1461

  Katsamakas, Sotirios ^a   Bermperoglou, Eleftherios ^a   Hadjipavlou Litina, Dimitra ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

2D QSAR; 3D mapping; Autotoxin inhibitors; Inflammation; Lipid mediators; Non lipid; PK descriptors

Indexed keywords

AUTOTAXIN INHIBITOR; BENZENE DERIVATIVE; HETEROCYCLIC COMPOUND; IMIDAZOLE DERIVATIVE; PHOSPHORIC ACID DERIVATIVE; PHOSPHOROTHIOIC ACID DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; US 2010249132A 1; US 2011230471A 1; US 2012059016A 1; US 2012115852A 1; US 8530650B 2; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; ENZYME INHIBITOR; PHOSPHODIESTERASE; PROTEIN BINDING;

CRYSTAL STRUCTURE; DRUG STRUCTURE; HYDROPHILICITY; IC50; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; X RAY DIFFRACTION; AREA UNDER THE CURVE; BINDING SITE; CHEMISTRY; HALF LIFE TIME; METABOLISM; MOLECULAR DYNAMICS; PROTEIN TERTIARY STRUCTURE; RECEIVER OPERATING CHARACTERISTIC;

AREA UNDER CURVE; BINDING SITES; ENZYME INHIBITORS; HALF-LIFE; MOLECULAR DYNAMICS SIMULATION; PHOSPHORIC DIESTER HYDROLASES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; ROC CURVE;

EID: 84931287737     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150227154253     Document Type: Review

References (81)

1. Sevastou, I.; Kaffe, E.; Mouratis, M. A.; Aidinis, V. Lysoglycerophospholipids in chronic inflammatory disorders: The PLA(2)/LPC and ATX/LPA axes. Biochim. Biophys. Acta, 2013, 1831 (1), 42-60.
2. Aoki, J.; Inoue, A.; Okudaira, S. Two pathways for lysophosphatidic acid production. Biochim. Biophys. Acta, 2008, 1781 (9), 513-8.
3. Aoki, J. Mechanisms of lysophosphatidic acid production. Semin. Cell Dev. Biol., 2004, 15 (5), 477-89.
4. Sano, T.; Baker, D.; Virag, T.; Wada, A.; Yatomi, Y.; Kobayashi, T.; Igarashi, Y.; Tigyi, G., Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J. Biol. Chem., 2002, 277 (24), 21197-206.
5. Umezu-Goto, M.; Kishi, Y.; Taira, A.; Hama, K.; Dohmae, N.; Takio, K.; Yamori, T.; Mills, G. B.; Inoue, K.; Aoki, J.; Arai, H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol., 2002, 158 (2), 227-33.
6. Stracke, M. L.; Krutzsch, H. C.; Unsworth, E. J.; Arestad, A.; Cioce, V.; Schiffmann, E.; Liotta, L. A. Identification, purification, and partial sequence analysis of autotaxin, a novel motilitystimulating protein. J. Biol. Chem., 1992, 267 (4), 2524-9.
7. (a) Giganti, A.; Rodriguez, M.; Fould, B.; Moulharat, N.; Coge, F.; Chomarat, P.; Galizzi, J. P.; Valet, P.; Saulnier-Blache, J. S.; Boutin, J. A.; Ferry, G. Murine and human autotaxin alpha, beta, and gamma isoforms: gene organization, tissue distribution, and biochemical characterization. J. Biol. Chem., 2008, 283 (12), 7776-89;
8. (b) Lee, H. Y.; Murata, J.; Clair, T.; Polymeropoulos, M. H.; Torres, R.; Manrow, R. E.; Liotta, L. A.; Stracke, M. L. Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. Biochem. Biophys. Res. Commun., 1996, 218 (3), 714-9.
9. Kishi, Y.; Okudaira, S.; Tanaka, M.; Hama, K.; Shida, D.; Kitayama, J.; Yamori, T.; Aoki, J.; Fujimaki, T.; Arai, H. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J. Biol. Chem., 2006, 281 (25), 17492-500.
10. Zhao, H.; Ramos, C. F.; Brooks, J. D.; Peehl, D. M. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J. Cell Physiol., 2007, 210 (1), 111-21.
11. Moolenaar, W. H.; Perrakis, A. Insights into autotaxin: how to produce and present a lipid mediator. Nat. Rev. Mol. Cell Bio., 2011, 12 (10), 674-679.
12. Nishimasu, H.; Ishitani, R.; Aoki, J.; Nureki, O. A 3D view of autotaxin. Trends Pharmacol. Sci., 2012, 33 (3), 138-45.
13. Nishimasu, H.; Okudaira, S.; Hama, K.; Mihara, E.; Dohmae, N.; Inoue, A.; Ishitani, R.; Takagi, J.; Aoki, J.; Nureki, O., Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat. Struct. Mol. Biol., 2011, 18 (2), 205-U271.
14. Hausmann, J.; Kamtekar, S.; Christodoulou, E.; Day, J. E.; Wu, T.; Fulkerson, Z.; Albers, H. M.; van Meeteren, L. A.; Houben, A. J.; van Zeijl, L.; Jansen, S.; Andries, M.; Hall, T.; Pegg, L. E.; Benson, T. E.; Kasiem, M.; Harlos, K.; Kooi, C. W.; Smyth, S. S.; Ovaa, H.; Bollen, M.; Morris, A. J.; Moolenaar, W. H.; Perrakis, A. Structural basis of substrate discrimination and integrin binding by autotaxin. Nat. Struct. Mol. Biol., 2011, 18 (2), 198-204.
15. The PyMOL Molecular Graphics System, Version 1.4.1, Schrödinger, LLC.
16. (a) Houben, A. J.; Moolenaar, W. H. Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev., 2011, 30 (3-4), 557-65;
17. (b) Liu, S.; Murph, M.; Panupinthu, N.; Mills, G. B. ATX-LPA receptor axis in inflammation and cancer. Cell Cycle, 2009, 8 (22), 3695-701.
18. Oikonomou, N.; Mouratis, M. A.; Tzouvelekis, A.; Kaffe, E.; Valavanis, C.; Vilaras, G.; Karameris, A.; Prestwich, G. D.; Bouros, D.; Aidinis, V. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol., 2012, 47 (5), 566-74.
19. Savaskan, N. E.; Rocha, L.; Kotter, M. R.; Baer, A.; Lubec, G.; van Meeteren, L. A.; Kishi, Y.; Aoki, J.; Moolenaar, W. H.; Nitsch, R.; Brauer, A. U. Autotaxin (NPP-2) in the brain: cell type-specific expression and regulation during development and after neurotrauma. CMLS, 2007, 64 (2), 230-43.
20. Umemura, K.; Yamashita, N.; Yu, X.; Arima, K.; Asada, T.; Makifuchi, T.; Murayama, S.; Saito, Y.; Kanamaru, K.; Goto, Y.; Kohsaka, S.; Kanazawa, I.; Kimura, H., Autotaxin expression is enhanced in frontal cortex of Alzheimer-type dementia patients. Neurosci. Lett., 2006, 400 (1-2), 97-100.
21. Hammack, B. N.; Fung, K. Y.; Hunsucker, S. W.; Duncan, M. W.; Burgoon, M. P.; Owens, G. P.; Gilden, D. H. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult. Scler., 2004, 10 (3), 245-60.
22. (a) Blaho, V. A.; Hla, T. Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem. Rev., 2011, 111 (10), 6299-320;
23. (b) Choi, J. W.; Herr, D. R.; Noguchi, K.; Yung, Y. C.; Lee, C. W.; Mutoh, T.; Lin, M. E.; Teo, S. T.; Park, K. E.; Mosley, A. N.; Chun, J. LPA receptors: subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol., 2010, 50 (1), 157-86.
24. Awada, R.; Rondeau, P.; Gres, S.; Saulnier-Blache, J. S.; Lefebvre d'Hellencourt, C.; Bourdon, E. Autotaxin protects microglial cells against oxidative stress. Free Radic. Biol. Med., 2012, 52 (2), 516-26.
25. Pontiki, E.; Hadjipavlou-Litina, D.; Geromichalos, G.; Papageorgiou, A. Anticancer activity and quantitative-structure activity relationship (QSAR) studies of a series of antioxidant/antiinflammatory aryl-acetic and hydroxamic acids. Chem. Biol. Drug Des., 2009, 74 (3), 266-75.
26. Mize, C. D.; Abbott, A. M.; Gacasan, S. B.; Parrill, A. L.; Baker, D. L., Ligand-based autotaxin pharmacophore models reflect structure-based docking results. J. Mol. Graph. Model., 2011, 31 (0), 76-86.
27. Gendaszewska-Darmach, E.; Laska, E.; Rytczak, P.; Okruszek, A. The chemical synthesis of metabolically stabilized 2-OMe-LPA analogues and preliminary studies of their inhibitory activity toward autotaxin. Bioorg. Med. Chem. Lett., 2012, 22 (8), 2698-700.
28. Gajewiak, J.; Tsukahara, R.; Fujiwara, Y.; Tigyi, G.; Prestwich, G. D. Synthesis, pharmacology, and cell biology of sn-2-aminooxy analogues of lysophosphatidic acid. Org. Lett., 2008, 10 (6), 1111-4.
29. North, E. J.; Howard, A. L.; Wanjala, I. W.; Pham, T. C.; Baker, D. L.; Parrill, A. L. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors. J. Med. Chem., 2010, 53 (8), 3095-105.
30. (a) Norman, D. D.; Ibezim, A.; Scott, W. E.; White, S.; Parrill, A. L.; Baker, D. L., Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds. Bioorg. Med. Chem., 2013, 21 (17), 5548-60;
31. (b) Parrill, A. L.; Echols, U.; Nguyen, T.; Pham, T. C.; Hoeglund, A.; Baker, D. L. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors. Bioorg. Med. Chem., 2008, 16 (4), 1784-95.
32. (a) Baker, D. L.; Fujiwara, Y.; Pigg, K. R.; Tsukahara, R.; Kobayashi, S.; Murofushi, H.; Uchiyama, A.; Murakami-Murofushi, K.; Koh, E.; Bandle, R. W.; Byun, H. S.; Bittman, R.; Fan, D.; Murph, M.; Mills, G. B.; Tigyi, G. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J. Biol. Chem., 2006, 281 (32), 22786-93;
33. (b) Cui, P.; McCalmont, W. F.; Tomsig, J. L.; Lynch, K. R.; Macdonald, T. L. alpha-and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors. Bioorg. Med. Chem., 2008, 16 (5), 2212-25;
34. (c) Durgam, G. G.; Tsukahara, R.; Makarova, N.; Walker, M. D.; Fujiwara, Y.; Pigg, K. R.; Baker, D. L.; Sardar, V. M.; Parrill, A. L.; Tigyi, G.; Miller, D. D. Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands. Bioorg. Med. Chem. Lett., 2006, 16 (3), 633-40;
35. (d) East, J. E.; Kennedy, A. J.; Tomsig, J. L.; De Leon, A. R.; Lynch, K. R.; Macdonald, T. L. Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX). Bioorg. Med. Chem. Lett., 2010, 20 (23), 7132-6;
36. (e) Gududuru, V.; Zeng, K.; Tsukahara, R.; Makarova, N.; Fujiwara, Y.; Pigg, K. R.; Baker, D. L.; Tigyi, G.; Miller, D. D. Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors. Bioorg. Med. Chem. Lett., 2006, 16 (2), 451-6;
37. (f) Gupte, R.; Patil, R.; Liu, J.; Wang, Y.; Lee, S. C.; Fujiwara, Y.; Fells, J.; Bolen, A. L.; Emmons-Thompson, K.; Yates, C. R.; Siddam, A.; Panupinthu, N.; Pham, T. C.; Baker, D. L.; Parrill, A. L.; Mills, G. B.; Tigyi, G.; Miller, D. D. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity. ChemMedChem., 2011, 6 (5), 922-35;
38. (g) Gupte, R.; Siddam, A.; Lu, Y.; Li, W.; Fujiwara, Y.; Panupinthu, N.; Pham, T. C.; Baker, D. L.; Parrill, A. L.; Gotoh, M.; Murakami-Murofushi, K.; Kobayashi, S.; Mills, G. B.; Tigyi, G.; Miller, D. D. Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid. Bioorg. Med. Chem. Lett., 2010, 20 (24), 7525-8;
39. (h) Jiang, G.; Madan, D.; Prestwich, G. D. Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin. Bioorg. Med. Chem. Lett., 2011, 21 (17), 5098-101;
40. (i) Valentine, W. J.; Kiss, G. N.; Liu, J.; Gotoh, M.; Murakami-Murofushi, K.; Pham, T. C.; Baker, D. L.; Parrill, A. L.; Lu, X.; Sun, C.; Bittman, R.; Pyne, N. J.; Tigyi, G. (S)-FTY720-vinylphosphonate, an analogue of the immunosuppressive agent FTY720, is a panantagonist of sphingosine 1-phosphate GPCR signaling and inhibits autotaxin activity. Cell Signal., 2010, 22 (10), 1543-53;
41. (j) Kawaguchi, M.; Okabe, T.; Okudaira, S.; Nishimasu, H.; Ishitani, R.; Kojima, H.; Nureki, O.; Aoki, J.; Nagano, T. Screening and Xray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe. ACS Chem. Biol., 2013, 8 (8), 1713-21.
42. BioByte Corporation, C-QSAR database, 201 W Fourth str., Suite # 204, Claremont, CA 91711-4707, USA.
43. Abraham, M. H.; Mcgowan, J. C. The Use of Characteristic Volumes to Measure Cavity Terms in Reversed Phase Liquid-Chromatography. Chromatographia, 1987, 23 (4), 243-246.
44. Golbraikh, A,; Tropsha, A. Beware of q2! Journal of molecular graphics & modelling 2002, 20 (4), 269-76
45. (a) Konc, J.; Cesnik, T.; Konc, J. T.; Penca, M.; Janezic, D. ProBiS-database: precalculated binding site similarities and local pairwise alignments of PDB structures. J. Chem. Inf. Model., 2012, 52 (2), 604-12;
46. (b) Konc, J.; Janezic, D., ProBiS-2012: web server and web services for detection of structurally similar binding sites in proteins. Nucleic Acids Res., 2012, 40 (Web Server issue), W214-21.
47. (a) Hoeglund, A. B.; Bostic, H. E.; Howard, A. L.; Wanjala, I. W.; Best, M. D.; Baker, D. L.; Parrill, A. L. Optimization of a pipemidic acid autotaxin inhibitor. J. Med. Chem., 2010, 53 (3), 1056-66;
48. (b) Hoeglund, A. B.; Howard, A. L.; Wanjala, I. W.; Pham, T. C.; Parrill, A. L.; Baker, D. L., Characterization of nonlipid autotaxin inhibitors. Bioorg. Med. Chem., 2010, 18 (2), 769-76.
49. (a) Schiemann. K. S. M.; Staehle, W. PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS. US Patent Application Publication 2012, US 2012/0059016 A1, pp 136;
50. (b) Schiemann, K. S. M.; Staehle W.; Kober I.; Wienke, D.; Krier, M. 2,5-DIAMINO-SUBSTITUTED PYRIDO [4,3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER. US Patent 2013, US 8,530,650 B2, pp 121;
51. (c) Schultz, M. S. K.; Botton G.; Blaukat A.; Kober, I. IMIDAZOE DERIVATIVES. US Patent Application Publication 2010, US 2010/0249132 A1, pp 73;
52. (d) Schultz M., Staehle W., HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS. US Patent Application Publication 2012, US 2012/0115852 A1, pp 141;
53. (e) Staehle W., Schiemann K., Schultz M., Wienke D., BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN. US Patent Application Publication 2011, US 2011/0230471 A1, pp 51.
54. Grant, J. A.; Gallardo, M. A.; Pickup, B. T. A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape. J. Comput. Chem., 1996, 17 (14), 1653-1666.
55. O'Boyle, N. M.; Banck, M.; James, C. A.; Morley, C.; Vandermeersch, T.; Hutchison, G. R. Open Babel: An open chemical toolbox. J. Chem. inform., 2011, 3 (1), 33.
56. (a) Hawkins, P. C.; Nicholls, A., Conformer generation with OMEGA: learning from the data set and the analysis of failures. J. Chem. Inf. Model., 2012, 52 (11), 2919-36;
57. (b) Hawkins, P. C.; Skillman, A. G.; Warren, G. L.; Ellingson, B. A.; Stahl, M. T. Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J. Chem. Inf. Model., 2010, 50 (4), 572-84.
58. Lovering, F.; Bikker, J.; Humblet, C. Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem., 2009, 52 (21), 6752-6.
59. (a) Marvin, Marvin was used for drawing, displaying and characterizing chemical structures, substructures and reactions, Marvin 14.9.29 , 2014 ChemAxon (http://www.chemaxon.com);
60. (b) Plugins, C., Calculator Plugins were used for structure property prediction and calculation, Marvin 14.9.29, 2014. ChemAxon (http://www.chemaxon.com).
61. (a) Albers, H. M.; Dong, A.; van Meeteren, L. A.; Egan, D. A.; Sunkara, M.; van Tilburg, E. W.; Schuurman, K.; van Tellingen, O.; Morris, A. J.; Smyth, S. S.; Moolenaar, W. H.; Ovaa, H. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc. Natl. Acad. Sci. U.S.A., 2010, 107 (16), 7257-62;
62. (b) Albers, H. M.; Hendrickx, L. J.; van Tol, R. J.; Hausmann, J.; Perrakis, A.; Ovaa, H., Structure-based design of novel boronic acid-based inhibitors of autotaxin. J. Med. Chem., 2011, 54 (13), 4619-26;
63. (c) Albers, H. M.; van Meeteren, L. A.; Egan, D. A.; van Tilburg, E. W.; Moolenaar, W. H.; Ovaa, H. Discovery and optimization of boronic acid based inhibitors of autotaxin. J. Med. Chem., 2010, 53 (13), 4958-67.
64. Katsamakas, S.; Hadjipavlou-Litina, D. Boronic acid based inhibitors of autotaxin: Understanding their biological role in terms of quantitative structure activity relationships (QSAR). Lett. Drug Des. Discov., 2013, 10 (1), 11-18.
65. Huang, N.; Shoichet, B. K.; Irwin, J. J. Benchmarking sets for molecular docking. J. Med. Chem., 2006, 49 (23), 6789-801.
66. Nicholls, A., What do we know and when do we know it? J. Comput. Aided Mol. Des., 2008, 22 (3-4), 239-55.
67. Gierse, J.; Thorarensen, A.; Beltey, K.; Bradshaw-Pierce, E.; Cortes-Burgos, L.; Hall, T.; Johnston, A.; Murphy, M.; Nemirovskiy, O.; Ogawa, S.; Pegg, L.; Pelc, M.; Prinsen, M.; Schnute, M.; Wendling, J.; Wene, S.; Weinberg, R.; Wittwer, A.; Zweifel, B.; Masferrer, J. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J. Pharmacol. Exp. Thers., 2010, 334 (1), 310-7.
68. Schiemann K., S. M. Blaukat A., Kober I., PIPERIDINE AND PIPERAZINE DERIVATIVES. US Patent Application Publication 2010, US 2010/0222341 A1, pp 82.
69. St-Coeur, P. D.; Ferguson, D.; Morin, P., Jr.; Touaibia, M. PF-8380 and closely related analogs: synthesis and structure-activity relationship towards autotaxin inhibition and glioma cell viability. Arch. Pharm. (Weinheim), 2013, 346 (2), 91-7.
70. Abdel-Magid, A. F. Autotaxin Inhibitors May Treat Pain and Osteoarthritis. ACS Med. Chem. Lett., 2014, 5 (10), 1072-1073.
71. Kawaguchi, M.; Okabe, T.; Okudaira, S.; Hanaoka, K.; Fujikawa, Y.; Terai, T.; Komatsu, T.; Kojima, H.; Aoki, J.; Nagano, T. Fluorescence probe for lysophospholipase C/NPP6 activity and a potent NPP6 inhibitor. J. Am. Chem. Soc., 2011, 133 (31), 12021-30.
72. (a) Lipinski, C. A. Lead-and drug-like compounds: The rule-of-five revolution. Drug Discov. Today Technol., 2004, 1 (4), 337-41;
73. (b) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46 (1-3), 3-26.
74. Ferry, G.; Moulharat, N.; Pradere, J. P.; Desos, P.; Try, A.; Genton, A.; Giganti, A.; Beucher-Gaudin, M.; Lonchampt, M.; Bertrand, M.; Saulnier-Blache, J. S.; Tucker, G. C.; Cordi, A.; Boutin, J. A. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J. Pharmacol. Exp. Therapeut., 2008, 327 (3), 809-19.
75. Jiang, G.; Xu, Y.; Fujiwara, Y.; Tsukahara, T.; Tsukahara, R.; Gajewiak, J.; Tigyi, G.; Prestwich, G. D. Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. Chem.Med.Chem., 2007, 2 (5), 679-90.
76. (a) Albers, H. M.; Ovaa, H. Chemical evolution of autotaxin inhibitors. Chem Rev 2012, 112 (5), 2593-603;
77. (b) Barbayianni, E.; Magrioti, V.; Moutevelis-Minakakis, P.; Kokotos, G. Autotaxin inhibitors: A patent review. Expert Opin. Ther. Pat., 2013, 23 (9), 1123-32;
78. (c) Boutin, J. A.; Ferry, G., Autotaxin. CMLS, 2009, 66 (18), 3009-21.
79. Pontiki, E.; Hadjipavlou-Litina, D., Lipoxygenase inhibitors: A comparative QSAR study review and evaluation of new QSARs. Med. Res. Rev., 2008, 28 (1), 39-117.
80. Hansch, C.; Kurup, A.; Garg, R.; Gao, H. Chem-bioinformatics and QSAR: A review of QSAR lacking positive hydrophobic terms. Chem. Rev., 2001, 101 (3), 619-72.
81. Hansch, C.; Klein, T. E. Molecular Graphics and Qsar in the Study of Enzyme Ligand Interactions-on the Definition of Bioreceptors. Acc. Chem. Res., 1986, 19 (12), 392-400.